Dermira announced results from ARIDO, a Phase 3 open-label extension study that assessed the long-term safety of topical, once-daily treatment with glycopyrronium tosylate in patients with primary axillary hyperhidrosis.
An additional 44 weeks of treatment demonstrated that glycopyrronium tosylate was well-tolerated and was associated with a low rate of discontinuation attributed to adverse effects; these findings were consistent with previous trial results.
During the 44-week treatment period, patients receiving glycopyrronium tosylate experienced a sustained response to therapy, maintaining reduced sweat production compared to baseline; these patients also reported less bothersome sweating. Moreover, the study found that mean sweat production decreased by 95.77 ±140.8mg/5min and 63.2% of patients had ≥2-grade improvement in the Hyperhidrosis Disease Severity Scale (HDSS).
Glycopyrronium tosylate is an anticholinergic agent administered as a topical wipe. It is designed to block sweat production by inhibiting the interaction between acetylcholine and cholinergic receptors responsible for sweat gland activation.
Findings from this study will be presented at the 36th Annual Fall Clinical Dermatology Conference in Las Vegas.
For more information visit Dermira.com.